Corilagin
Based on 8 publication(s) in Google Scholar
Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues.
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 23094-69-1
- Formula: C27H22O18
- Molecular Weight:634.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Corilagin
More- Front Immunol. 2022 Jan 13;12:807509. [Abstract]
- Eur J Pharmacol. 2025 Nov 5:1006:178158. [Abstract]
- World J Diabetes. 2024 Sep 15;15(9):1916-1931. [Abstract]
- Cancer Sci. 2024 Oct;115(10):3466-3480. [Abstract]
- FASEB J. 2025 Mar 15;39(5):e70439. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Fitoterapia. 2024 Jan:172:105743. [Abstract]
- Ann Hematol. 2026 Feb 11;105(3):107. [Abstract]
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Flow Cytometry
-
ELISA
Biological Activity
Corilagin (0-50 μM, 24 h) inhibits SGC7901 and BGC823 cell growth, and the cells became rounded[2].
Corilagin (0-30 μM, 24 h) induces SGC7901 and BGC823 cell apoptosis[2].
Corilagin (0-30 μM, 24 h) decreased the protein levels of procaspase-8, -9 and -3 and increases cleaved PARP in SGC7901 and BGC823 cell[2].
Corilagin (0-30 μM, 24 h) induces autophagy in SGC7901 and BGC823 cell (enhancement of acidic vesicles, increased the level of LC3II)[2].
Corilagin (0-30 μM, 24 h) induces ROS generation in SGC7901 and BGC823 cell[2].
Corilagin (40 μM, 24 or 48 h) induces G2 cell cycle arrest and apoptosis in Hey and SKOv3ip cells[3].
Corilagin (0-80 μM, 1-3 days) inhibits the secretion of TGF-β1 in Hey, SKOv3ip and HO8910PM cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SGC7901 and BGC823 cell
-
Concentration:0, 10, 20, 30, 40 and 50 µM
-
Incubation Time:24 h
-
Result:Inhibited cell proliferation in a concentration-dependent manner.
-
Cell Line:SGC7901 and BGC823 cell
-
Concentration:0, 10, 20, 30 µM
-
Incubation Time:24 h
-
Result:Decreased the protein levels of procaspase-8, -9 and -3 and increased the level of cleaved PARP.
Corilagin (0-20 mg/kg, i.p.) prevents APAP-induced hepatotoxicity in mice[5].
Corilagin (10 and 100 mg/kg, i.p.) ameliorates Bleomycin-induced pulmonary fibrosis in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hep3B hepatocellular carcinoma mouse model[4].
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth without toxic effects.
-
Animal Model:APAP-induced hepatotoxicity in mice[5]
-
Dosage:0, 1, 5, 10, 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Decreased APAP-induced serum ALT level, hepatic myeloperoxidase (MPO) activity, cytokines (TNF-α, IL-1β, and IL-6) production, malondialdehyde (MDA) activity, and ERK/JNK MAPK and NF-κB protein expressions.
Chemical Information
-
CAS No. 23094-69-1
-
Appearance Solid
-
Molecular Weight 634.45
-
Formula C27H22O18
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@H](COC(C2=C(C3=C(O)C(O)=C(O)C=C34)C(O)=C(O)C(O)=C2)=O)O[C@@H](OC(C5=CC(O)=C(O)C(O)=C5)=O)[C@H](O)[C@H]1OC4=O
-
Synonyms
NP-004255
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Front Immunol
Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization. [Abstract]2022 Jan 13;12:807509. PMID: 35095894
Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]
Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Corilagin treatment significantly reduced the MDA level and increased the activity of SOD compared with the Con A group.
Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]
Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. MPO levels in the corilagin-treated group were significantly reduced compared with those in the Con A-treated group.
Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]
Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. The results showed that corilagin treatment markedly attenuated hepatocyte apoptosis induced by Con A.
Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]
Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Detection of the macrophage ratio in mouse hepatic mononuclear cells (HMNCs) by flow cytometry.
Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]
Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Inflammatory cytokines interleukin (IL)-6, IL-12, and tumor necrosis factor-α (TNF-α) in the serum measured by ELISA.
-
Eur J Pharmacol
Corilagin alleviates cardiac ischemia-reperfusion injury by inhibiting ferroptosis via PI3K/AKT pathway. [Abstract]2025 Nov 5:1006:178158. PMID: 40962010 -
World J Diabetes
Corilagin alleviates podocyte injury in diabetic nephropathy by regulating autophagy via the SIRT1-AMPK pathway. [Abstract]2024 Sep 15;15(9):1916-1931. PMID: 39280180 -
Cancer Sci
CLG promotes mTOR/ULK1 pathway-mediated autophagy to inhibit OS development by inhibiting TRAF6-mediated FLT3 ubiquitination. [Abstract]2024 Oct;115(10):3466-3480. PMID: 39118482 -
FASEB J
Corilagin enhances wound healing by modulating the macrophage phenotype in diabetic mice. [Abstract]2025 Mar 15;39(5):e70439. PMID: 40052815 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Fitoterapia
Polyphenol-enriched extracts of Sarcopoterium spinosum fruits for counteracting lipid accumulation and oxidative stress in an in vitro model of hepatic steatosis. [Abstract]2024 Jan:172:105743. PMID: 37952761 -
Ann Hematol
Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway. [Abstract]2026 Feb 11;105(3):107. PMID: 41670696
Solvent & Solubility
DMSO : 100 mg/mL (157.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 5.88 mg/mL (9.27 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li X, et al. Corilagin, a promising medicinal herbal agent. Biomed Pharmacother. 2018 Mar;99:43-50. [Content Brief]
[2]. Xu J, et al. Corilagin induces apoptosis, autophagy and ROS generation in gastric cancer cells in vitro. Int J Mol Med. 2019 Feb;43(2):967-979. [Content Brief]
[3]. Jia L, et al. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med. 2013 Feb 15;13:33. [Content Brief]
[4]. Hau DK, et al. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine. 2010 Dec 15;18(1):11-5. [Content Brief]
[5]. Liu FC, et al. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF-κB signaling pathway in a mouse model. Am J Transl Res. 2020 Sep 15;12(9):5597-5607. [Content Brief]
[6]. Wang Z, et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci. 2014 May 30;15(6):9762-79. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5762 mL | 7.8808 mL | 15.7617 mL | 39.4042 mL |
| 5 mM | 0.3152 mL | 1.5762 mL | 3.1523 mL | 7.8808 mL | |
| 10 mM | 0.1576 mL | 0.7881 mL | 1.5762 mL | 3.9404 mL | |
| 15 mM | 0.1051 mL | 0.5254 mL | 1.0508 mL | 2.6269 mL | |
| 20 mM | 0.0788 mL | 0.3940 mL | 0.7881 mL | 1.9702 mL | |
| 25 mM | 0.0630 mL | 0.3152 mL | 0.6305 mL | 1.5762 mL | |
| 30 mM | 0.0525 mL | 0.2627 mL | 0.5254 mL | 1.3135 mL | |
| 40 mM | 0.0394 mL | 0.1970 mL | 0.3940 mL | 0.9851 mL | |
| 50 mM | 0.0315 mL | 0.1576 mL | 0.3152 mL | 0.7881 mL | |
| 60 mM | 0.0263 mL | 0.1313 mL | 0.2627 mL | 0.6567 mL | |
| 80 mM | 0.0197 mL | 0.0985 mL | 0.1970 mL | 0.4926 mL | |
| 100 mM | 0.0158 mL | 0.0788 mL | 0.1576 mL | 0.3940 mL |